Raffaele Colombo, Associate Director of Medicinal Chemistry at Zymeworks, shared an article by Xuenan Peng, et al. on X:
“New publication of a retrospective study of ADC after ADC!
Not surprisingly, for HER2-positive:
‘Patients who received ADC2 with a different payload from ADC1 exhibited significantly longer PFS2 (6.8 vs. 2.7 mo) and overall PFS (15.0 vs. 8.5 mo)'”
The Ideal Strategies of Antibody‒Drug Conjugate Sequential Treatment in HER2-expressing Metastatic Breast Cancer: A Multi-Center Real-World Study
Authors: Xuenan Peng, Fei Ma, et al.
Paolo Tarantino, Advanced Research Fellow at Dana-Farber Cancer Institute, shared this post adding:
“Given the supposed mechanism of action of ADCs, it originally seemed logical that resistance would derive from the mAb target. The evidence, however, is proving this theory wrong.
Tumors become largely resistant to the chemo payload.”
